UK Aims To Quadruple Patient Recruitment To Industry Clinical Trials By 2027

Jun 01 2023

• By Vibha Sharma

Listen to this article

The UK government has set aside dedicated funds to deliver ambitious changes that would make it quicker and easier for companies to trial more of their products in the National Health Service.

Young businessman thinks over the steps for successful growth: Clinical trial — UK Wants To Speed Up The Delivery Of Commercial Trials And Boost Patient Involvement • Source: Shutterstock

The UK government has conveyed its seriousness about reversing the evident decline in commercial clinical trial activity in the country by promising “decisive action” on all 27 recommendations from an independent review on this topic.

Key Takeaways

Acting swiftly on recommendations from an independent review into how to improve the current state of commercial clinical trials in the UK, the government has pledged five new funding commitments totalling £121m.

A budget of £121m ($150m) has been set aside over three years to deliver five key commitments on a priority...

More from United Kingdom

Responsible Antimicrobial Manufacturing A Must For UK’s Subscription Model Applicants
Aug 27 2024
• By Eliza Slawther
The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.
Use AI In Health Technology Assessments Only When Valuable, England’s NICE Tells Pharma Firms
Aug 22 2024
• By Eliza Slawther
Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.
Leqembi's UK Rollercoaster: A Yes From MHRA, A No From NICE
Aug 22 2024
• By Neena Brizmohun
While the drug regulator has approved Eisai/Biogen’s early Alzheimer’s disease treatment, the health technology assessment institute is worried that its benefits are too small to justify its costs – a concern that Eisai has pledged to address.
Working With The Inspectors: UK’s eXmoor Gets License To Make ATMPs
Aug 21 2024
• By Eliza Slawther
It is “absolutely fundamental” that manufacturers of cell and gene therapies interact with inspectors from regulatory agencies to understand their expectations around good manufacturing practice, a compliance consultant at CDMO eXmoor pharma says.

More from Europe

EU Biosimilar Filings, Opinions And Approvals
Oct 07 2024
• By Saba Afreen
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials
Oct 03 2024
• By Neena Brizmohun
Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.
How To Decarbonize Pharma R&D
Oct 02 2024
• By Francesca Bruce
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.